(R)-3-(4-phenoxyphenyl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dihydrochloride
Product Intro
This is the intermediate of irutinib. Ibrutinib is a Bruton tyrosine kinase (Btk) inhibitor for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
Function
Irutinib can combine with Btk, which is necessary for the formation, differentiation, information transmission and survival of B lymphocytes, irreversibly inhibit the activity of BTK and effectively inhibit the proliferation and survival of tumor cells
Application
Ibrutinib is an inhibitor of BTK kinase. It can covalently bind with cysteine residues in the active center of BTK, so as to inhibit the activity of B cells. It has a significant effect on B-cell lymphoma, especially for patients with a variety of advanced lymphomas that are difficult to relapse.
Copyright © Shanghai Norky Pharmaceutical Co., Ltd. All Rights Reserved 沪ICP备20013299号 Powered by www.300.cn